"I am continually inspired by the leadership of the ABC2 team and their complete dedication to the improvement of the outcomes of brain cancer patients. We all work together to rapidly bring the newest approaches and ideas forward — whether it's a basic research finding or a new approach for treatment or diagnosis. We are colleagues and friends, which makes the work even more enjoyable and the success that we achieve even more rewarding."
Al is the Kenan Distinguished Professor of Biology and Associate Director of the Lineberger Comprehensive Cancer Center at the University of North Carolina School of Medicine. His research focuses on understanding the involvement of the NF-kappaB transcription factor pathway in promoting oncogenesis and driving cancer therapy resistance. Al is the author of over 150 peer-reviewed manuscripts and is the founder of TheraLogics, a company directed at inhibiting the NF-kappaB pathway in a variety of cancers and human diseases.